MedTrace Logo

Epcoritamab for the Treatment of Relapsed or Refractory Post Transplant Lymphoproliferative Disorders

NCT06672705 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 26

Last updated 2025-08-19

No results posted yet for this study

Summary

This phase Ib trial tests the safety and effectiveness of epcoritamab in treating patients with post-transplant lymphoproliferative disorder (PTLD) that has come back after a period of improvement (relapsed) or has not responded to previous treatment (refractory). Epcoritamab, a bispecific antibody, binds to a protein called CD3, which is found on T cells (a type of white blood cell). It also binds to a protein called CD20, which is found on B cells (another type of white blood cell) and some lymphoma cells. This may help the immune system kill cancer cells. Giving epcoritamab may be safe and effective in treating patients with relapsed or refractory B-cell PTLD.

Conditions

  • Diffuse Large B-Cell Lymphoma Post-Transplant Lymphoproliferative Disorder
  • EBV-Related Post-Transplant Lymphoproliferative Disorder
  • Recurrent Monomorphic Post-Transplant Lymphoproliferative Disorder
  • Recurrent Polymorphic Post-Transplant Lymphoproliferative Disorder
  • Refractory Monomorphic Post-Transplant Lymphoproliferative Disorder
  • Refractory Polymorphic Post-Transplant Lymphoproliferative Disorder

Interventions

PROCEDURE

Biopsy

Undergo biopsy

PROCEDURE

Biospecimen Collection

Undergo blood sample collection

PROCEDURE

Computed Tomography

Undergo PET/CT

BIOLOGICAL

Epcoritamab

Given SC

PROCEDURE

Positron Emission Tomography

Undergo PET/CT

Sponsors & Collaborators

  • AbbVie

    collaborator INDUSTRY

  • Genmab

    collaborator INDUSTRY

  • Timothy Voorhees

    lead OTHER

Principal Investigators

  • Timothy J Voorhees, MD · Ohio State University Comprehensive Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-06-16
Primary Completion
2026-12-31
Completion
2026-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06672705 on ClinicalTrials.gov